Statements (88)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Planned_Parenthood
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:FDA
1970s |
| gptkbp:available_in |
various dosages
generic form |
| gptkbp:brand |
gptkb:Loestrin_1/20
gptkb:Loestrin_Fe gptkb:Loestrin_24_Fe combination hormonal contraceptive |
| gptkbp:can |
gptkb:Skin
polycystic ovary syndrome regulating menstrual cycle endometriosis management |
| gptkbp:clinical_trial |
side effects
Phase III safety profile safety and efficacy studies adverse effects studies long-term use studies contraceptive efficacy |
| gptkbp:contains |
gptkb:norethindrone_acetate
gptkb:ethinyl_estradiol |
| gptkbp:contraindication |
liver disease
certain cancers history of blood clots smoking over age 35 |
| gptkbp:developed_by |
gptkb:Pfizer
|
| gptkbp:discontinued |
gptkb:Loestrin_24_Fe
gptkb:Loestrin_21 |
| gptkbp:dosage_form |
gptkb:tablet
combination pill |
| gptkbp:effective_date |
gptkb:1993
|
| gptkbp:financial_support |
store at room temperature
keep out of reach of children consult healthcare provider do not skip doses report unusual symptoms |
| gptkbp:formulation |
oral tablet
combination oral contraceptive |
| https://www.w3.org/2000/01/rdf-schema#label |
Loestrin
|
| gptkbp:ingredients |
gptkb:norethindrone_acetate
gptkb:ethinyl_estradiol |
| gptkbp:interacts_with |
antibiotics
anticonvulsants HIV medications |
| gptkbp:is_effective_against |
over 99% with perfect use
91% with typical use |
| gptkbp:manufacturer |
gptkb:Abb_Vie
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:United_Kingdom gptkb:United_States various brand names |
| gptkbp:marketing_strategy |
patient assistance programs
direct-to-consumer advertising physician samples |
| gptkbp:mechanism_of_action |
prevents ovulation
thickens cervical mucus thins uterine lining |
| gptkbp:monitoring_requirement |
blood pressure
cholesterol levels liver function |
| gptkbp:packaging |
blister pack
|
| gptkbp:patient_population |
women of reproductive age
postpartum women provided with prescription women with irregular cycles |
| gptkbp:provides_guidance_on |
ACOG recommendations
CDC medical eligibility criteria |
| gptkbp:regulatory_body |
gptkb:FDA
gptkb:EMA TGA |
| gptkbp:requires |
gptkb:true
prescription only |
| gptkbp:side_effect |
headache
nausea hypertension breast tenderness mood changes thromboembolism gallbladder disease liver tumors |
| gptkbp:storage |
room temperature
|
| gptkbp:used_for |
contraception
regulating menstrual cycles |
| gptkbp:bfsParent |
gptkb:Ortho_Tri-Cyclen_Lo
|
| gptkbp:bfsLayer |
6
|